Home > Sickle Cell Disease > Efficacy > Extension data

In this section:

Extension Data

Long-term Serum Ferritin Reductions
Demonstrated in Sickle Cell Disease

Serum Ferritin Trends Decrease Over 6 Years
Long-term Serum Ferritin Reductions

Study 109 was extended to further analyze the long-term efficacy and safety of EXJADE in patients with transfusion-dependent sickle cell disease.
Only 43 out of the original 132 patients entered the sixth year.

EXJADE SAFETY
PROFILE ACROSS
ANEMIAS

Learn more